Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | CLPP | Q16740 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528676 | 0.93 | HDAC1 (0.54) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6502433 | 0.91 | CXCR3 (0.46) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6487407 | 0.91 | CLPP (0.53) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6489979 | 0.91 | HDAC1 (0.52) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6494740 | 0.90 | HDAC1 (0.54) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6533092 | 0.90 | HDAC1 (0.51) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6488570 | 0.88 | HDAC1 (0.52) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6488384 | 0.88 | HDAC1 (0.49) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6487938 | 0.88 | HDAC1 (0.51) | HDAC1HDAC6HDAC10CLPPCXCR3 | |
| SCHEMBL6495720 | 0.85 | TP53 (0.45) | HDAC1HDAC6HDAC10CLPPCXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | HDAC1 199/4885HDAC6 503/4885HDAC10 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.